BIRC2 is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CARD11 is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79A is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79B is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IRAK1 is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IRAK1 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

JAK3 is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYD88 is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NFKBIA is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TYK2 is an inclusion eligibility criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TYK2 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].